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—————————————————————————————————————
Covariate adjustment is an important tool in the analysis of randomized clinical trials
and observational studies. It can be used to increase efficiency and thus power, and
to reduce possible bias. While most statistical tests in randomized clinical trials
are nonparametric in nature, approaches for covariate adjustment typically rely on
specific regression models, such as the linear model for a continuous outcome, the
logistic regression model for a dichotomous outcome and the Cox model for survival
time. Several recent efforts have focused on model-free covariate adjustment. This
paper makes use of the empirical likelihood method and proposes a nonparametric
approach to covariate adjustment. A major advantage of the new approach is that it
automatically utilizes covariate information in an optimal way without fitting non-
parametric regression. The usual asymptotic properties, including the Wilks-type
result of convergence to a χ2 distribution for the empirical likelihood ratio based test,
and asymptotic normality for the corresponding maximum empirical likelihood esti-
mator, are established. It is also shown that the resulting test is asymptotically most
powerful and that the estimator for the treatment effect achieves the semiparametric
efficiency bound. The new method is applied to the Global Use of Strategies to Open
Occluded Coronary Arteries (GUSTO)-I trial. Extensive simulations are conducted,
validating the theoretical findings.
KEY WORDS: Estimating Equation; Likelihood Ratio Test; Semiparametric Effi-
ciency; Wilks Theorem.
—————————————————————————————————————
Xiaoru Wu is PhD candidate, Department of Statistics, Columbia University, New
York, NY 10027 (Email: xw2144@columbia.edu) and Zhiliang Ying is Professor,
Department of Statistics, Columbia University, New York, NY 10027 (Email: zy-
ing@stat.columbia.edu). The authors thank the Virtual Coordinating Center for
1
2Global Collaborative Cardiovascular Research (VIGOUR) Leaders for the use of
GUSTO-I data. This research was supported by grants from the National Institutes
of Health and the National Science Foundation.
31. INTRODUCTION
Testing for the statistical significance of treatment differences is a key element in
the analysis of randomized clinical trials. In its simplest form, patients are randomly
allocated to either a treatment or control group and their responses are recorded.
Many statistical methods are available for testing whether there is convincing evi-
dence that a treatment difference exists between the two groups; cf. Pocock (1983)
and Friedman, Furberg and DeMets (1998). In addition to treatment allocation and
outcome values, baseline covariate information is often collected in such clinical stud-
ies. Classical analysis of covariance (ANCOVA) and other regression model-based
tests may be used to handle covariate adjustment; cf. Scheffe (1959), Simon (1984),
McCullagh and Nelder (1989) and Rutter and Elashoff (1994). When properly used,
covariate adjustment can increase efficiency and, in the case of an observational study,
reduce bias (Armitage 1981).
Due to randomization, most two-sample (multi-sample if more than two treatment
groups are involved) tests are valid without any parametric assumption. Therefore,
these tests are nonparametric in nature, a feature of great importance in a clinical
trial. Standard methods for covariate adjustment, however, require that a specific
regression model be assumed; see, for example, Piantadosi (2005, Chapter 17).
Adjusting for covariates without assuming a regression model has been studied by
Koch (1998), Tsiatis, Davidian, Zhang and Lu (2008) among others. In particular,
Koch (1998) proposed a weighted least squares method to include covariate informa-
tion for estimating the treatment difference. This method always leads to a variance
reduction, thus an increase in power. By appealing to semiparametric efficiency the-
ory, Tsiatis et al. (2008) developed a general approach to covariate adjustment that
circumvents modeling the covariate-outcome relationship. Their approach allows for
nonlinear terms in relating the auxiliary covariates to the outcome variable, thereby
further reducing the variability. They showed that the method is semiparametrically
efficient by deriving the semiparametric information bound and by showing the bound
is attained with their approach.
4An essential ingredient in the approach by Tsiatis et al. (2008) is the use of the
independence of treatment allocation and baseline covariates to construct equations
associated. These equations can be viewed as constraints that, when properly utilized,
may lead to further reduction in variability of the outcome variable. How to optimally
use these constraints is therefore crucial for efficiency improvement.
Empirical likelihood (Owen 1988) is a general method for efficiently utilizing con-
straints or estimating equations. Specifically, it maximizes the nonparametric like-
lihood (Kiefer and Wolfowitz 1956) subject to certain constraints that are specific
to the problem of interest. It can be used to obtain empirical likelihood ratio tests
as well as confidence intervals. Examples include testing and interval estimation for
population means and for regression coefficients. Qin and Lawless (1994) showed
that the constraints can be used more liberally in the sense that the number of con-
straints may exceed the number of parameters of interest. They also showed that the
empirical likelihood utilizes the information in the constraints in an optimal way.
Because baseline covariate information for a randomized clinical trial generates
constraints, it is natural to consider the empirical likelihood as a means to improve
efficiency for the primary problem of testing and estimating treatment difference. To
that end, this paper proposes a general approach to covariate adjustment by making
use of the empirical likelihood and suitably choosing constraints. The new approach
does not require any model assumption on the relationship between the outcome
variable and baseline covariates. It is shown that such an empirical likelihood based
method automatically results in efficiency improvement. For testing, it is asymp-
totically most powerful; for estimation, it achieves the semiparametric information
bound.
The rest of the paper is organized as follows. In Section 2 we introduce some
notation and briefly discuss existing model-based methods. We apply the empirical
likelihood method for covariate adjustment and extend it to inference with growing
number of constraints in Section 3. The design and results of simulation studies
are described in Section 4. In Section 5, the method is applied to a study of acute
myocardial infarction. Some concluding remarks are given in Section 6.
52. NOTATION AND MODEL SPECIFICATION
In a (K+1)-arm (K ≥ 1) randomized clinical trial, for subject i, let Yi, Zi andX i
denote the outcome, treatment allocation and available auxiliary baseline covariates,
respectively. Assume that (Yi, Zi,X i), i = 1, . . . , n, are independent and identically
distributed (i.i.d.) and that the random allocation probabilities pik = P (Z = k),
k = 0, . . . , K, where
∑K
k=0 pik = 1, are known.
Throughout, Gk denotes the conditional distribution of the outcome variable Y
given treatment allocation Z = k, k = 0, . . . , K. Then the usual null hypothesis of
no treatment difference is given by
H0 : G
0 = G1 = . . . = GK .
Note that there is no assumption on the form of {Gk, k = 0, . . . , K}.
To study treatment effects, one may choose certain contrasts among the treatment
groups in terms of their population characteristics, for example, the difference in
mean outcomes between two treatment groups. Following Zhang et al. (2008), the
treatment effect can be identified by considering
(1) β1 = E(Y |Z = 0), β2 = E(Y |Z = 1)− E(Y |Z = 0),
or equivalently, by formulating
E(Y |Z) = β1 + β2Z.(2a)
Clearly, such an approach does not require model assumption on the underlying
distribution functions Gk, k = 0, . . . , K. If there are more than two treatment groups,
equation (2a) becomes
E(Y |Z) = β1 + β21(Z=1) + . . .+ βK+11(Z=K),(2b)
where 1(·) is the indicator function and βk+1 represents the difference in mean outcome
between group k and group 0. For a binary outcome, an alternative formulation is
via the log-odds ratios:
(3) logit{P (Y = 1|Z)} = log
{
P (Y = 1|Z)
P (Y = 0|Z)
}
= β1 + β21(Z=1) + . . .+ βK+11(Z=K).
6Under this formulation, testing the null hypothesis of no treatment difference is tan-
tamount to testing H0 : β2 = . . . = βK+1 = 0, and estimating the treatment effect is
tantamount to estimating values of the βk, k = 2, . . . , K + 1. For notational conve-
nience, we use β to denote the parameter vector (β1, . . . , βK+1)
T .
Besides the outcome variable and treatment assignment, relevant baseline co-
variates, which may comprise patients’ demographic information, medical history,
lifestyle measurements, etc., may be recorded as well. Their association with and
impact on the outcome variable can then be explored for efficiency gains in testing
and estimation of treatment effects. A common approach to adjusting for covariates
is to postulate a certain regression model, which gives treatment comparisons condi-
tional on values of the covariates. It is well known that treatment effects may have
different interpretations in conditional and unconditional (on covariate value) models.
Indeed, except for linear and exponential regression models, the conditional and un-
conditional approaches generally lead to different parameter values for the treatment
effect. We refer to Gail (1984) for a comprehensive discussion on the subject.
Since the unconditional treatment effect is of primary interest here, it is natural for
us to avoid any modeling of the relationship between the outcome variable and base-
line covariates. Yet it is also desirable that we make best use of the information in
the covariates to improve efficiency. To this end, we explore the empirical likelihood
methodology to develop a model-free approach to covariate adjustment. We demon-
strate that such an approach is natural for nonparametric covariate adjustment and
optimal in terms of efficient use of available information.
3. EMPIRICAL LIKELIHOOD BASED METHODS FOR
NONPARAMETRIC COVARIATE ADJUSTMENT
Being first implicitly used in Thomas and Grunkemeier (1975), empirical likelihood
was developed into a general methodology by Owen (1988, 1990). Given (Yi, Zi,X i),
i = 1, . . . , n, assumed to be independent with a common cumulative distribution
function (CDF) F0, the empirical likelihood function is a nonparametric likelihood
function of the CDF F
7(4) L(F ) =
n∏
i=1
dF (yi, zi,xi) =
n∏
i=1
pi,
where (yi, zi,xi) is the observed value of (Yi, Zi,X i), pi = dF (yi, zi,xi) = P (Yi =
yi, Zi = zi,X i = xi), i = 1, . . . , n. Without additional constraints (other than pi ≥ 0
and
∑n
i=1 pi = 1), it is well known that the empirical distribution function is the
nonparametric maximum likelihood estimate of F0.
This section is devoted to the development of an empirical likelihood based method
for nonparametric covariate adjustment arising from a typical randomized clinical
trial. Subsection 3.1 develops an empirical likelihood ratio based test and establishes
its asymptotic properties. The subsequent subsection deals with the dual problem of
estimating treatment effects via maximizing the empirical likelihood with the number
of constraints exceeding the number of parameters. Subsection 3.3 extends the results
of 3.1 and 3.2 to the situation in which the number of constraints increases with
the sample size. Asymptotic normality and Wilks type χ2 approximation as well
as asymptotic efficiency are established for all the cases under suitable regularity
conditions.
3.1 Testing Treatment Differences
Empirical likelihood methodology for inference is based on maximizing the nonpara-
metric likelihood (4) subject to appropriately formulated and problem-specific con-
straints. For the two-arm randomized clinical trial specified by (2a), the constraints
are generated by
m(β; Y, Z) = (1, Z)T (Y − β1 − β2Z).(5a)
For general K specified by (2b), it becomes
m(β; Y, Z) = (1, 1(Z=1), . . . , 1(Z=K))
T (Y − β1 − β21(Z=1) − . . .− β(K+1)1(Z=K)).
(5b)
The zero-mean property ofm(β; Y, Z) uniquely determines the value of β and can be
used to obtain estimators through the sample-generated estimating equations. The
resulting inference involves only the Yi and Zi.
8The availability of the baseline covariates X i should enable us to obtain addi-
tional estimating equations, thereby additional constraints. Indeed, Davidian et al.
(2005) and Leon et al. (2003) found that the following form gives a general family of
estimating equations:
(6)
K∑
k=0
(1(Z=k) − pik)hk(X),
where hk, k = 0, 1, . . . , K are arbitrary functions. The independence of Z and X
guarantees the zero-mean property of the resulting estimating equations.
It is clear now that the number of zero-mean estimating equations as provided by
(5) and (6) exceeds the number of parameters which specify the treatment effect.
In fact, the number of possible equations that can be generated from (6) can be
unlimited when the baseline covariatesX are continuous. Suppose we fix the choice of
hk and consider how to make use of them for efficiency improvement. For notational
simplicity, we use gr(β; Y, Z,X) to denote an r-vector of the resultant estimating
equations that include both (5) and (6). Here r ≥ 2 in the two-sample case and
r ≥ K + 1 for the general (K + 1)-sample case.
It is well known that the empirical likelihood approach links together the inference
of certain parameters and the available estimating equations to form a constrained
optimization problem. With constraints given by gr, it maximizes L(F ) in (4) subject
to the following constraints:
(7) pi ≥ 0,
n∑
i=1
pi = 1,
n∑
i=1
pigr(β; Yi, Zi,X i) = 0.
This optimization problem has a unique maximizer provided that 0 is inside the
convex hull of {gr(β; yi, zi,xi), i = 1, . . . , n} for a given β (Owen 2001). By apply-
ing the Lagrange multiplier argument (Lang 1987), we can easily get pi = {n[1 +
λ̂
T
(β)gr(β; yi, zi,xi)]}−1, where λ̂, which is a function of β, is the solution to
(8)
1
n
n∑
i=1
gr(β; yi, zi,xi)
1 + λ̂
T
(β)gr(β; yi, zi,xi)
= 0.
Therefore, the resulting profile empirical log-likelihood, as a function of β, takes form
(9) lE(β) =
n∑
i=1
log
[
1 + λ̂
T
(β)gr(β; yi, zi,xi)
]
.
9Theorem 3.1. Let βT = (βT1 ,β
T
2 ), where β1 and β2 are q1- and q2-vectors. Define
(10) TE = 2lE(β̂10, 0)− 2lE(β̂),
the logarithmic empirical profile likelihood ratio for testing H˜0 : β2 = 0, where β̂10
minimizes lE(β1, 0) with respect to β1 and β̂ minimizes lE(β). Then, under some
mild regularity conditions, TE converges to χ
2
(q2)
in distribution under H˜0.
Theorem 3.1 is a direct adaptation of Corollary 5 in Qin and Lawless (1994). It
enables us to get the p-value in testing the null hypothesis of no treatment difference
and to invert the test to obtain the confidence limits. A numerical way to find β̂,
and similarly for β̂10, is to use a two-stage Newton algorithm. We first specify an
initial value β(0) for β and solve (8) to obtain λ̂(β(0)). Next, we fix λ̂(β) in (9) at
λ̂(β(0)) and minimize (9) over β to obtain a new value β(1). We iterate the process
until convergence.
From Qin and Lawless (1994), it follows that the empirical likelihood ratio test
incorporating covariate information through constraints gr(β; Y, Z,X) is always more
powerful than the one with m(β; Y, Z) only. Moreover, the more constraints we
put into gr, the more powerful the test becomes. Because the net effect of the
empirical likelihood method with more constraints than parameters is an optimal
linear combination of the constraints, choice of additional constraints should therefore
be made to avoid redundancy. However, it is not necessary to model the relationship
between the covariates and the outcome, as is evident from equation (6); this is a
very desirable feature with important practical implications.
For a binary outcome variable, if we are interested in using the log-odds ratio, then
we can replace (5b) with
m(β; Y, Z) = (1, 1(Z=1), . . . , 1(Z=K))
T [Y − φ(β1 + β21(Z=1) + . . .+ β(K+1)1(Z=K))],
where φ(·) = exp(·)/[1+ exp(·)] is the logistic function. We can then follow the same
steps to construct the empirical likelihood ratio test. As before, the large sample
properties given by Theorem 3.1 continue to hold.
10
3.2 Maximum Empirical Likelihood Estimate of Treatment Effect
Without adjusting for baseline covariates, the number of estimating equations, de-
rived from the score functions, equals the number of parameters. Solving equations∑n
i=1m(β; Yi, Zi) = 0 gives us the M-estimator for β, which is known to be consis-
tent and asymptotically normal (Huber 1981). With covariate adjustment, we have
additional estimating equations containing auxiliary information through (6). Since
the number of all available estimating equations r exceeds the number of parameters
q = q1+ q2, we cannot obtain the estimators simply by finding zeros of those estimat-
ing equations. One way to handle overly constrained problem is to form q-dimensional
linear combinations of all available estimating equations so that the resulting set of
equations has a unique solution. One can further evaluate the limiting covariance
matrix of the estimator to identify the optimal choice of such linear combinations; cf.
Goldambe and Heyde (1987). Because the empirical likelihood method with overly
constrained estimating equations can result in the optimal combination (Qin and
Lawless 1994), it provides a nature alternative. The following result follows directly
from Qin and Lawless (1994).
Theorem 3.2. Let Dr = E[∂gr(β0)/∂β
T ] and Σr = E(grg
T
r ). Then, under certain
regularity conditions, we have
(11) n1/2(β̂ − β0)→ N
(
0, (DTrΣ
−1
r Dr)
−1
)
,
where β̂ is the maximum empirical likelihood estimate (MELE).
The theorem above allows us to construct Wald-type confidence intervals using
the robust variance estimate. From Corollary 2 of Qin and Lawless (1994), it fol-
lows that β̂ has the smallest asymptotic variance among all the q-dimensional linear
combinations of gr(β; Y, Z,X). In particular, when r = q, the maximum empirical
likelihood estimator β̂ will be asymptotically equivalent to the M-estimator. Fur-
thermore, Corollary 1 of Qin and Lawless (1994) ensures that the more constraints
being put into the optimization problem, the more precision one can achieve.
As an example, consider again a two-arm clinical trial with a binary outcome
variable and a continuous covariate X , and suppose the log-odds ratio is of interest.
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We can incorporate both linear and quadratic terms of X by using constraints
gr(β; Y, Z,X) =
(
(1, Z)[Y − φ(β1 + β2Z)], (Z − pi1), (Z − pi1)X, (Z − pi1)X2
)T
.
The resulting estimator will be more efficient than the M-estimator from (1, Z)T [Y −
φ(β1 + β2Z)]. Note that, for regression model based covariate adjustment, Robinson
and Jewell (1991) demonstrated that including predictive covariates in the logit will
always result in a loss of precision. In contrast, for our empirical likelihood approach,
including predictive covariates in the constraints will never lead to an increase in
the asymptotic variance. The fact that incoporating additional estimating equations
always improves efficiency makes the empirical likelihood approach advantageous and
convenient.
3.3 Empirical Likelihood With Growing Number of Constraints
Since we can achieve more precision by increasing the number of constraints, it is
intuitive that semiparametric efficiency may be attained when the number of con-
strains grows with the sample size. In this connection, we consider in this subsection
the empirical likelihood based covariate adjustment when the number of constraints
grows to infinity as n→∞. Note here that the dimension of β, which is of primary
concern, remains fixed.
Suppose besides the q-dimensional score m(β; Y, Z), the auxiliary information is
contained in an rn-vector of estimating equations g
∗
rn(β) = (m
T (β; Y, Z),V Tn )
T .
Instead of a fixed number r, rn here will grow to infinity with n at a certain rate. The
jth component of V n has the form (1(Z=k)− pik)hj(X) for j = 1, . . . , rn− q, where hj
is a real-valued function. The following conditions will be used.
(C1) There exists a non-random (rn − q) × (rn − q) matrix W n such that (i)-(iii)
below are satisfied for grn(β) = (m
T (β; Y, Z), (W nVn)
T )T .
(i) Components of gn,i, i = 1, . . . , n, are uniformly bounded by a finite constant
M > 0, where gn,i(β) = grn(β; Yi, Zi,X i).
(ii) Eigenvalues ofΣn,g = E(grn(β0)g
T
rn(β0)) are bounded away from zero and infinity.
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(iii) There exists a q × (rn − q) non-random matrix An such that
AnW nV n →
K∑
k=0
(1(Z=k) − pik)E(m(β; Y, Z)|Z = k,X) in L2.
(C2) The growth rate of rn is limited to r
3
n = o(n).
(C3) Matrix Σ˜ = E(m˜m˜
T
) is positive definite, where
m˜ =m(β; Y, Z)−
K∑
k=0
(1(Z=k) − pik)E(m(β; Y, Z)|Z = k,X).
Theorem 3.3. Let β̂n be the maximum empirical likelihood estimate based on con-
straints g∗rn(β) and Dm = E(∂m(β0)/∂β
T ). Then, under Conditions C1-C3,
(12) n1/2(β̂n − β0)→ N
(
0, (DTmΣ˜
−1
Dm)
−1
)
.
Minimizing the asymptotic variance of the M-estimator from the class of arbitrary
q-dimensional unbiased estimating equations, Zhang et al. (2008) derived the semi-
parametric efficiency bound for the estimators of treatment effect. From Zhang et al.
(2008) and Theorem 3.3, we have the following result.
Corollary 3.4. The limiting variance-covariance matrix, (DTmΣ˜
−1
Dm)
−1, achieves
the semiparametric efficiency bound, i.e., β̂n in Theorem 3.3 is asymptotically effi-
cient.
In practice, in order to construct the Wald type confidence interval for β0, we need
to estimate the asymptotic variance expressed in (12). Let gn(β) = n
−1
∑n
i=1 gn,i(β),
Sn(β) = n
−1
∑n
i=1 gn,i(β)g
T
n,i(β) and Dˆ(β) = ∂gn(β)/∂β
T . Theorem 3.5 below
shows that a consistent estimate of the limiting variance-covariance matrix of n1/2(β̂n−
β0) is [Dˆ(βˆn)S
−1
n (β̂n)Dˆ(βˆn)]
−1.
Theorem 3.5. Under Conditions C1-C3,
∥∥∥Dˆ(βˆn)S−1n (β̂n)Dˆ(βˆn)−DTmΣ˜−1Dm∥∥∥ =
op(1).
Throughout, ‖·‖ is used to denote the Euclidean norm. Theorem 3.3 states that the
listed conditions are sufficient to ensure standard asymptotic properties of the MELE.
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Moreover, Corollary 3.4 states that when the number of constraints grows to infinity
at a certain rate, the MELE achieves the semiparametric efficiency as derived in
Zhang (2008). In Theorem 3.3, grn is essentially a linear transformation of g
∗
rn . Since
a linear transformation does not change the constraints, the estimator using grn will
be the same as that using g∗rn. The fact that the MELE will not be affected by a linear
transformation of the constraints greatly facilitates the applicability of the empirical
likelihood approach because we can just throw in all the constraints we have without
forming the appropriate combination of them. For example, E[g∗rn(g
∗
rn)
T ] might be
ill conditioned but we can still use it as long as there exists a W n such that the
corresponding Σn,g is better conditioned. For this reason, we will not distinguish
among linear transformations of constraints in the following discussion.
Theorem 3.3 holds for a general q-dimensional score m as long as some regularity
conditions in the case of fixed number of constraints (Qin and Lawless 1994) are
satisfied, including E
(
∂m(β; Y, Z)/∂βT
)
is of full rank p,
∥∥∂m(β; Y, Z)/∂βT∥∥ and∥∥∂2m(β; Y, Z)/∂β∂βT∥∥ can be bounded by some integrable function in a neighbor-
hood of β0 and ∂m(β; Y, Z)/∂β and ∂
2m(β; Y, Z)/∂β∂βT are continuous in this
neighborhood.
Condition C2 imposes an upper bound on the growth rate of the number of con-
straints at which a well-behaved MELE can be obtained. In practice, the number
of constraints need not be large. In fact, we find that additional gain by including
an extra constraint diminishes quickly, due to the optimal use of constraints by the
empirical likelihood method. It is important to note that the asymptotic normality
and efficiency are not affected by the choice of rn, as long as it satisfies C2. It is
certainly of theoretical interest to find the sharp upper bound for rn to grow such
that the resulting estimate is still asymptotically normal and efficient. But we will
not get into this complication here since finding the optimal rate is not our main
concern. If we knew the conditional expectations in Condition C3, the optimal es-
timating equations m˜ would be the constraints that lead to the optimal estimator.
Although they are unknown in practice, it is clear that Condition C3 is fairly mild.
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For Condition C1, we need to make use of the orthogonality and boundedness of cer-
tain basis functions to properly design h(X) in the constraints. Suppose Z = 0, 1, 2
and the empirical CDF of the one dimensional auxiliary covariate X is Fn(x) =
n−1
∑n
i=1 1{Xi≤x}. By making use of multivariate Fourier expansion, the arguments
can be generalized to the high dimensional auxiliary covariate case. Let g∗rn(β) =
(mT (β; Y, Z), (11−pi1), ŝ11, ĉ11, . . . , ŝ1dn , ĉ1dn , (12−pi2), ŝ21, ĉ21, . . . , ŝ2dn , ĉ2dn)T , where
1k = 1(Z=k), rn = 4dn+q+2, ŝij = (1i−pii) sin(2pijFn(X)), ĉij = (1i−pii) cos(2pijFn(X)),
i = 1, 2, j = 1, . . . , dn. It can be shown that, when dn = o(n
1/4), (i)-(iii) are satis-
fied. For example, we can apply the fact that those basis functions are orthogonal
when their arguments are U [0, 1] and they are bounded to show (i) and (ii) hold.
Because the procedure is invariant under linear transformations, the eigenvalues can
grow with n if all of them grow at the same rate. However, we do not believe in
general they can grow at different rates since the covariance matrix is sandwiched in
the variance-covariance expression, which needs to be well-conditioned. Furthermore,
(iii) can be verified by taking the expansion of the conditional expectations. Likewise,
we may apply other orthogonal basis functions that are bounded. For example, we
can use the Legendre polynomials of (2Fn(X)− 1) which are bounded by 1 on [-1,1].
Legendre polynomials, i.e. 1, x, (3x2− 1)/2, . . ., are linear transformations of polyno-
mial terms 1, x, x2, . . .. Therefore we can also use polynomial terms of (2Fn(X)− 1)
in the auxiliary constraints due to linear transformation invariance of the empirical
likelihood. As pointed out by a referee, the standard independence assumption for
empirical likelihood is violated due to the plug-in estimator Fn. Intuitively, the valid-
ity of using Fn instead of F relies on the fact that those constraints are still zero-mean
conditioning on all the covariates. A rigorous proof can be found in the Appendix.
Analogous to the case with a fixed number of constraints, let l(β) =
∑n
i=1 log
(
1+
λ̂
T
n (β)gn,i(β)
)
. The empirical likelihood ratio statistic for testing H0 : β = β0 is
(13) T1n = 2l(β0)− 2l(β̂n).
Then under Conditions C1-C3, the Wilks type theorem of convergence to the χ2
distribution is still valid for testing the null hypothesis of no treatment effect.
15
Theorem 3.6. Suppose that Conditions C1-C3 are satisfied. Then, under the null
hypothesis H0, T1n converges in distribution to χ
2
(q) as n→∞.
More generally, we can test hypothesis on a subset of treatment effects β instead
of all components of it. For instance, we may be interested in testing whether β2 = 0
in the simple example (2a). Specifically, let βT = (βT1 ,β
T
2 )
T , where β1 and β2 are
q1- and q2-vectors, respectively. For H˜0 : β1 = β10, the profile empirical likelihood
ratio test statistic is simply
(14) T2n = 2l(β10, β̂20)− 2l(β̂n),
where β̂20 minimizes l(β10,β2) with respect to β2. The following result shows that
a Wilks type χ2 approximation still holds.
Corollary 3.7. Suppose that Conditions C1-C3 are satisfied. Then, under the null
hypothesis, T2n converges in distribution to χ
2
(q1)
as n→∞.
Auxiliary information can be used to not only increase the precision of estimated
treatment effects, but to also increase power in hypothesis testing. To evaluate power,
we need to derive the asymptotic distribution of the test statistic under the alternative
hypothesis. We shall consider the contiguous alternative which deviates from the null
by the order of O(n−1/2); cf. Hajek, Sidak and Sen (1999) and Serfling (1980). For
notational convenience, let A = DTmΣ˜
−1
Dm and write
A =

A11 A12
A21 A22

 ,
where Aij = E(∂m
T (β0)/∂βi)Σ˜
−1
E(∂m(β0)/∂β
T
j ), i = 1, 2 and j = 1, 2.
Theorem 3.8. Suppose that Conditions C1-C3 are satisfied. Then under the se-
quence of contiguous alternatives Ha : β = βa = β0 +h/
√
n, the empirical likelihood
ratio test statistic T1n converges in distribution to a noncentral χ
2 with degrees of
freedom q and noncentrality parameter hTAh.
Similarly, the noncentrality parameter of the limiting χ2 distribution becomes the
projected Fisher information when there are nuisance parameters.
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Corollary 3.9. Under the same assumptions as those in Theorem 3.8 and with Ha
replaced by H˜a : β1 = β1a = β10 + h1/
√
n, the empirical likelihood ratio test statistic
T2n in (14) converges in distribution to a noncentral χ
2 with degrees of freedom q1
and noncentrality parameter hT1 (A11 −A12A−122A21)h1.
It can be seen that the empirical likelihood approach reproduces the standard
asymptotic results in parametric likelihood theory (Cox and Hinkley 1974). Similar
to the estimation problem, adding more constraints will result in more powerful tests.
When the number of constraints goes to infinity, the corresponding tests become
asymptotically most powerful.
4. NUMERICAL STUDIES
In this section, we discuss computational issues arising from implementing the
constrained optimization problems and report simulation results associated with the
empirical likelihood based covariate adjustment method.
The primary step in computing the empirical likelihood is to maximize (4) subject
to constraints (7). The lagrangian is
P⋆(p,β,λ, γ) =
n∑
i=1
log⋆(pi) + nλ
T
n∑
i=1
pigr(β; yi, zi,xi) + nγ(
n∑
i=1
pi − 1),
where λ and γ are the Lagrange multipliers and log⋆ is a modified natural logarithm
defined in Owen (2001). Thus, we obtain estimators for p and β by differentiating
P⋆ with respect to p, β, λ and γ and setting them to 0.
Working directly with n + q + r + 1 free variables involves gradient and Hessian
matrices of daunting dimensions. Alternatively we may use the two-stage Newton
algorithm as discussed in Section 3.1 that can eliminate some parameters. Nonethe-
less, unlike the usual testing case where β is fixed at β0, the outer stage in the
two-stage Newton algorithm, i.e. minimization over β while keeping λ fixed, is dif-
ficult in practice because of the possibility of a non-positive definite Hessian ma-
trix. Zedlewski (2008) points out that “Concentrating out some parameters leads
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to a smaller optimization problem, but it can make it more difficult. Thus the two-
stage Newton algorithm is fast but unreliable and can lead to frustrating convergence
problems. In most cases n is much greater than q + r, so the largest block of the
Hessian is an n×n diagonal matrix.”. In our implementation, we use a Matlab pack-
age “matElike”, which solves the primal problem by including modern optimization
codes exploiting matrix sparsity. We find the package to be both robust and fast.
The link to the Matlab package and the code to implement our method can be found
at http://www.stat.columbia.edu/~xwu/software.html.
4.1 Estimation
The simulation results reported below are all based on 5000 Monte Carlo replications.
The sample size is chosen to be 200 throughout. We consider the case of two treatment
groups with the treatment indicator Z generated with P (Z = 0) = P (Z = 1) = 0.5.
The response variable Y is binary with logit{E(Y |Z)} = β1 + β2Z. The parameter
of interest is either β = (β1, β2)
T or β2.
In the first scenario, the auxiliary covariate X is generated as a one dimensional
Normal random variable with mean 0 and different variances. The magnitude of the
variance correlates with the influence of X on the response. Given Z and X , Y is
then generated as Bernoulli according to logit{P (Y = 1|Z = g,X)} = α0g + αgX ,
where α00 = 0.3, α01 = 1, α0 = 1, α1 = 1.5 and g = 0 or 1.
From Table 1 we see that when the standard deviation of X is 2, the Monte Carlo
standard errors gradually decrease and approach the optimal ones. From “marginal”
to “5 Fourier”, the standard errors drop significantly. However, additional constraints
beyond “5 Fourier” do not appear to have much impact on further variance reduction.
Note that a large number of additional constraints require substantially more com-
puting time. Thus, we will only compare the results of “marginal” with “5 Fourier”
in the other cases. A single (i.e., nonparallel) process that calculates the maximum
empirical likelihood estimate and the p-value for testing the null hypothesis of no
treatment difference takes, on average, less that 2 seconds to run for a data set of
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200 samples using 5 constraints. The computation time is estimated using a 2.33GHz
processor on a server with 8GB RAM.
Table 1 also shows that the means of Monte Carlo estimates differ from the true
value of β at the third decimal place and the coverage probabilities are around 0.95.
The Monte Carlo standard errors of estimates from five estimating equations are
generally smaller than those from marginal models. The improvement becomes more
pronounced when the variance of X becomes larger. Also, the average length of 95%
Wald confidence intervals are smaller than those of marginal models.
In the second scenario, the link function is quadratic in X, i.e., logit{P (Y = 1|Z =
g,X)} = α0g + αgX2, with the same α0g and αg values, g = 0, 1. From Table 2, we
see that the coverage probabilities are satisfactory and close to their nominal levels
as in the first scenario. The biases are slightly larger, however, they are still small
relative to the standard errors. As expected, the Monte Carlo standard errors and
the average lengths of 95% Wald confidence intervals from five estimating equations
are smaller than those from the two marginal ones.
In the third scenario, there are two auxiliary covariates X1 and X2 and the response
Y is generated as logit{P (Y = 1|Z = g,X)} = α0g + α1gX1 + α2gX2, g=0,1, with
α00 = 0.3, α01 = 1, α10 = 1, α11 = 1.5, α20 = 2, α21 = 1.5. The estimating equations
for the marginal method remain the same since there is no covariate adjustment
involved. Let κ(Z) =
√
2(2Z − 1) and Wk = 2piFn(Xk), k = 1, 2. The empirical
likelihood method with constraints, κ(Z), κ(Z) sin(W1), κ(Z) cos(W1), κ(Z) sin(W2),
κ(Z) cos(W2), except the marginal estimating equations is denoted by “7 Fourier”.
From Table 3, the performance of the estimates is similar to the previous two scenar-
ios.
4.2 Testing
With the same data generating process as in the preceding subsection, the corre-
sponding hypothesis testing results are presented in Tables 4, 5 and 6. In each
scenario, the profile empirical likelihood ratio test is used to test the null hypothesis
H˜0 : β2 = 0. CovProb denotes coverage probabilities for testing β2 = β20. We have
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the following observations. First, in all three tables, both coverage probabilities of
the profile empirical likelihood ratio tests are close to the nominal 95% level. Second,
the attained power from 5 estimating equations is larger than that from marginal
estimating equations. Third, when X is one dimensional, the gain in power is more
significant as the standard deviation of X increases.
5. APPLICATION
We apply the proposed empirical likelihood based approach to the Global Use of
Strategies to Open Occluded Coronary Arteries (GUSTO)-I trial data, which were
kindly provided to us by Karen Pieper from the Duke Clinical research Institute.
The primary endpoint was 30-day death, which occurred in 6.29% of 10366 patients
randomly assigned to tissue plasminogen activator (TPA) (g=1), 7.32% of 10354 pa-
tients randomly assigned to skreptokinase (SK) with IV heparin (g=2), 6.99% of
10303 patients randomly assigned to a combination of SK and TPA (g=3) and 7.24%
of 9773 patients randomly assigned to SK with SQ heparin (g=4). Besides treatment
assignment and outcome, some baseline auxiliary covariates concerning demographics
(age, sex, weight, height), risk factors (hypertension, diabetes, smoking, hypercholes-
terolemia), other history (family history of MI, previous MI, previous angina, previous
revascularization) and presenting characteristics (blood pressure, tachycardia, ante-
rior infarct location, killip class, ST elevation on electrocardiography) were recorded
on each subject. In Steyerberg et al. (2000), the relative prognostic strength of 17
baseline covariates was evaluated by their univariate χ2 model, which was calculated
as the difference in -2 log-likelihood between a univariate logistic regression model
with and without the characteristic. The strongest prognostic factor was age and this
was further confirmed by the R2 measure on the log-likelihood scale, which approxi-
mately indicated the percentage of variance explained. Except for the calculation of
correlation, adjustment for important predictors such as age is always recommended
in the case of short-term death after acute myocardial infarction. Thus, we will
compare unadjusted and age-adjusted results for the four treatment groups.
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The marginal model between the 30-day death (Y) and treatment assignment (Z)
is given by logit{E(Y |Z)} = β1 + β21(Z=2) + β31(Z=3) + β41(Z=4). For the age(X)
adjustment, we use 9 auxiliary constraints (1(Z=g) − 0.25), (1(Z=g) − 0.25)Fn(x) and
(1(Z=g) − 0.25)F 2n(x), g = 2, 3, 4, where Fn(x) is the empirical c.d.f. of age.
The unadjusted estimates (β̂1, β̂2, β̂3, β̂4) are (-2.7014, 0.1630, 0.1129, 0.1517) with
standard errors (0.04109, 0.05619, 0.05670, 0.05557). Estimates adjusted for age are
(-2.7014, 0.1628, 0.1126, 0.1521) with standard errors (0.04109, 0.05619, 0.05670,
0.05556). The p-values for the unadjusted and adjusted hypothesis testing of β2 =
β3 = β4 = 0 are 0.0136 and 0.0135, respectively.
The unadjusted test is already significant, so the additional improvement in p-value
after covariate adjustment only reconfirms the scientific conclusion. However, if the
sample size were smaller, the change in p-value might be more consequential. For
illustrative purposes, we randomly draw a subsample of size 20000 from the complete
data and pretend that is what we had in reality. In one of these cases, the p-values
for the unadjusted test of β2 = β3 = β4 = 0 is 0.0391 while it becomes 0.0362 after
adjusting for age. In another case, it changes from 0.0508 to 0.0458.
6. DISCUSSION
Nonparametric covariate adjustment is of importance in analysis of randomized
clinical trial data. When properly done, it can result in efficiency improvement while
maintaining the nonparametric nature of the usual tests. Empirical likelihood ap-
proach is nonparametric, constraint based and efficient in extracting information from
data.
For randomized clinical trials, covariate information with no model assumption
can be extracted from certain type of constraints or estimating equations. We pro-
pose an empirical likelihood based approach for covariate adjustment. The resulting
likelihood ratio test is shown to have the usual Wilks type χ2 approximation, with
increased power as the number of constraints increases. The corresponding max-
imum empirical likelihood estimate also enjoys similar asymptotic properties. We
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demonstrate that the χ2 and normal approximations continue to hold as the num-
ber of constraints grows with sample size. We further show that in doing so the
semiparametric efficiency can be achieved.
One of the practical issues is how to select basis functions in the constraints. From
our experiences with simulations and real data analysis, it appears that there is no
universal way to deal with this issue. A related issue is how many basis functions
should be used. One ad hoc way to do that is to consider variance reduction when
additional constraints are added. We believe that if initial basis functions are properly
chosen, then only a very small number of constraints will be needed.
It will be of interest to extend this empirical likelihood based nonparametric co-
variate adjustment to other situations, including observational studies. Of particular
importance are the survival and longitudinal studies where the response variables may
be dependent or causal. For survival data, Lu and Tsiatis (2008) have introduced
a general model framework for covariate adjustment and derived a semiparametric
efficient score. We believe a similar approach, which makes use of suitable covariate
based constraints and achieves the asymptotic efficiency, can be developed.
APPENDIX
Here we provide proofs of the theoretical results presented in the previous sections.
For notational convenience, letGn(β) = max
1≤i≤n
∥∥gn,i(β)∥∥, Σn,m = E(mrn(β0)mTrn(β0)),
Σn,opt = E(m
opt
rn (β0)(m
opt
rn (β0))
T ), Drn = E(∂grn(β0)/∂β
T ), Dmn = E(∂mrn(β0)/∂β
T ),
and Dopt = E(∂m
opt
rn (β0)/∂β
T ).
Lemma 1. The probability that zero is outside the convex hull spanned by {gn,i, i =
1, . . . , n} goes to zero as n→∞.
Proof. This follows from Lemma 4.2 in Hjort et al. (2009) and discussions thereof.

Lemma 2. Under (i),(ii) and C2, the eigenvalues of Sn(β0) are bounded away from
0 and ∞.
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Proof. It can be shown by making use of proofs of condition (D4) and Lemma 4.5
in Hjort et al. (2009). 
Lemma 3. Under (i),(ii) and C2,
∥∥∥λ̂n(β0)∥∥∥ = Op(n−1/2r1/2n )(15)
sup
‖β−β0‖≤n
−1/3
∥∥∥λ̂n(β)∥∥∥ = Op(n−1/3)(16)
sup
‖β−β0‖≤n
−1/3
∥∥∥λ̂n(β)− Sn(β)−1gn(β)∥∥∥ = Op(n−2/3r1/2n ).(17)
Proof. Under (i),(ii) and C2, we can apply results in Portnoy (1988) to get
(18)
∥∥n1/2gn(β0)∥∥ = Op(r1/2n ).
Under (i),
(19) Gn(β) ≤Mr1/2n = Op(r1/2n ).
Write λ̂n(β) =
∥∥∥λ̂n(β)∥∥∥un(β), where ‖un(β)‖ = 1. Then similar to (8), we can
show that
0 = uTn (β)
1
n
n∑
i=1
gn,i(β)
1 + λ̂
T
n (β)gn,i(β)
≤ uTn (β)gn(β)−
∥∥∥λ̂n(β)∥∥∥
1 +
∥∥∥λ̂n(β)∥∥∥Gn(β)mineig(Sn(β)),
where mineig(M ) stands for the minimum eigenvalue of the matrix M . Therefore,
we have
(20)
∥∥∥λ̂n(β)∥∥∥ (mineig(Sn(β))− uTn (β)gn(β)Gn(β)) ≤ uTn (β)gn(β),
from which we know that (15) holds due to (18), (19) and Lemma 2.
When ‖β − β0‖ ≤ n−1/3, define
(21) Ln = max
j,k
|Sn,j,k(β)− Sn,j,k(β0)| .
Using the same technique as in Lemma 2, rnLn = op(1) ensures that the minimum
eigenvalue of Sn(β) is bounded away from zero. Since there are only finitely many
terms in grn containing β, due to the δ-method, this can be further reduced to
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‖β − β0‖ = o(r−1n ), which is true under C2. By expanding gn(β) in the n−1/3 neigh-
borhood of β0, we obtain gn(β) = Op(n
−1/3) uniformly in ‖β − β0‖ ≤ n−1/3. Then
(16) follows from equation (20).
We know that λ̂n(β) satisfies the constraint n
−1
∑n
i=1 gn,i(β)/{1+λ̂
T
n (β)gn,i(β)} =
0, which implies
(22)
λ̂n(β) = Sn(β)
−1gn(β)+Sn(β)
−1 1
n
n∑
i=1
gn,i(β)
uTn (β)gn,i(β)g
T
n,i(β)un(β)
1 + λ̂
T
n (β)gn,i(β)
∥∥∥λ̂n(β)∥∥∥2 .
By the triangle inequality and some simple algebra, the final term in (22) is bounded
by Op(n
−2/3r
1/2
n ). Since ‖Sn(β)−1‖ = Op(1), (17) follows from (22). 
Lemma 4. Under Conditions C1-C3,
∥∥∥DTrnΣ−1n,gDrn −DTmΣ˜−1Dm∥∥∥ = o(1).
Proof. Let mrn = m(β; Y, Z) +AnW nV n. Since AnW nV n does not involve β,
we have
(23) DTmnΣ
−1
n,mDmn = D
T
mΣ
−1
n,mDm,
which by (iii), converges to DTmΣ˜
−1
Dm.
Second, following Qin and Lawless (1994), for any n, we have
DTrnΣ
−1
n,gDrn =D
T
optΣ
−1
n,optDopt,
wheremoptrn = Aopt(β)grn is a q-vector and Aopt(β) is the optimal linear combination
of grn . So it suffices to show the following difference is zero:
(24) DToptΣ
−1
n,optDopt −DTmΣ−1n,mDm.
Given (23), (24) is positive definite due to optimality. Furthermore,
DToptΣ
−1
n,optDopt −DTmΣ−1n,mDm
= DToptΣ
−1
n,optDopt −DTmΣ˜
−1
Dm +D
T
mΣ˜
−1
Dm −DTmΣ−1n,mDm.
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By Zhang et al. (2008), we know that DTmΣ˜
−1
Dm is the semiparametric efficiency
bound, which implies the first difference is non-positive definite. Since the second
difference is op(1), we know (24) is nonpositive definite. 
Lemma 5. Under (i), (ii) and C2,
∥∥∥β̂n − β0∥∥∥ < n−1/3.
Proof. We first consider β on the n−1/3 sphere of β0, i.e. β − β0 = un−1/3, where
u is a unit vector. On the one hand, by the Taylor series expansion and Lemma 3,
2
n∑
i=1
log
(
1 + λ̂
T
n (β)gn,i(β)
)
= 2nλ̂
T
n (β)gn(β)− nλ̂
T
n (β)Sn(β)λ̂n(β) +Op(r
1/2
n ).
By (17), it is equivalent to ngTn (β)S
−1
n (β)gn(β) + Op(r
1/2
n ). By taking the Taylor
series expansion at β0, it equals to
uTDTrnΣ
−1
n,gDrnun
1/3 + op(n
1/3),
which is bounded below by Op(n
1/3) by Lemma 4. On the other hand, 2
∑n
i=1 log
(
1+
λ̂
T
n (β0)gn,i(β0)
)
= Op(rn), which is strictly less than Op(n
1/3) by condition C2.
Therefore,
∥∥∥β̂n − β0∥∥∥ < n−1/3. 
Lemma 6. Under conditions C1-C3, we have the asymptotic normality of the “in-
fluence function”
DTrnΣ
−1
n,gn
1/2gn(β0)→ N(0,DTmΣ˜
−1
Dm).
Proof. We can reduce the problem to the unidimensional case by noting that it
suffices to show that for any q × 1 vector t,
(25) tTDTrnΣ
−1
n,gn
1/2gn(β0)→ N(0, tTDTmΣ˜
−1
Dmt).
First, the variance of the left hand side of (25) is tTDTrnΣ
−1
n,gDrnt, which converges
to tTDmΣ˜
−1
Dmt by Lemma 4.
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Second, we verify the Lindeberg condition (Billingsley 1986)
n∑
i=1
E
{[
n−1/2tTDTrnΣ
−1
n,ggn,i(β0)
]2
1[∣
∣
∣n−1/2tTDTrnΣ
−1
n,ggn,i(β0)
∣
∣
∣>ε
]}
= E
{[
tTDTrnΣ
−1
n,ggrn(β0)
]2
1[∣
∣
∣tTDTrnΣ
−1
n,ggrn (β0)
∣
∣
∣>n1/2ε
]}→ 0,
where the last step comes from
P
( ∣∣tTDTrnΣ−1n,ggrn(β0)∣∣ > n1/2ε
)
≤ E
(
tTDTrnΣ
−1
n,ggrn(β0)
)2/
nε2,
which goes to 0 since the numerator is asymptotically bounded. Hence Lemma 6
holds by the Lindeberg-Feller Central Limit Theorem. 
Proof of Theorem 3.3. LetUn(β,λ) = 1n
∑n
i=1
gn,i(β)
1+λT gn,i(β)
and V n(β,λ) = 1n
∑n
i=1
λ∂gTn,i(β)/∂β
1+λT gn,i(β)
.
We know that (β̂n, λ̂n) satisfies Un(β̂n, λ̂n) = 0 and V n(β̂n, λ̂n) = 0. By taking the
Taylor series expansion, we have
0 = Un(β̂n, λ̂n)
= gn(β0) + Dˆ
T
(β0)(β̂n − β0)− Sn(β0)λ̂n +Op(n−2/3r1/2n ), and(26)
0 = V n(β̂n, λ̂n)
= Dˆ
T
(β0)λ̂n +Op(n
−2/3).(27)
Solving (26) and (27) for β̂n − β0, we get,
(28) n1/2(β̂n−β0) = −n1/2(Dˆ(β0)TS−1n (β0)Dˆ(β0))−1Dˆ(β0)S−1n (β0)gn(β0)+op(1).
By triangular inequality and Lemma 4, we can show that
(29)
∥∥∥(DˆT (β0)S−1n (β0)Dˆ(β0))−1 − (DTmΣ˜−1Dm)−1∥∥∥ = op(1).
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By Lemma 6,
Dˆ
T
(β0)S
−1
n (β0)n
1/2gn(β0) = D
T
rnΣ
−1
n,gn
1/2gn(β0) + op(n
−1/2+εr1/2n )
→ N(0,DTmΣ˜
−1
Dm).
Then Theorem 3.3 follows from (28), (29) and Slutsky’s Theorem. 
Proof of Theorem 3.5. Since there are only finitely many terms in gn and Sn that
contain β, by the δ-method, we have
∥∥∥(DˆT (β̂n)S−1n (β̂n)Dˆ(β̂n))−1 − (DˆT (β0)S−1n (β0)Dˆ(β0))−1∥∥∥ = op(1).
Then the result follows from (29). 
Proof of Theorem 3.6. Taking the Taylor series expansion, we get
T1n = n
1/2(β̂n − β0)T
[ ∂2
∂β∂βT
1
n
n∑
i=1
log
(
1 + λ̂
T
n (β0)gn,i(β0)
)]
n1/2(β̂n − β0) + op(1)
= n1/2(β̂n − β0)TAn1/2(β̂n − β0) + op(1).
Then Theorem 3.3 implies T1n → χ2q as n→∞, when H0 is true. 
Proof of Corollary 3.7. When only β1 is specified in the null hypothesis, we write
the likelihood ratio statistic as the sum of two differences, each of which can be
expanded in a manner similar to that in Theorem 3.6 and we have
T2n =
[
2
n∑
i=1
log
(
1 + λ̂
T
n (β0)gn,i(β0)
)
− 2
n∑
i=1
log
(
1 + λ̂
T
n (β̂n)gn,i(β̂n)
)]
−
[
2
n∑
i=1
log
(
1 + λ̂
T
n (β0)gn,i(β0)
)
− 2
n∑
i=1
log
(
1 + λ̂
T
n (β10, β̂20)gn,i(β10, β̂20)
)]
= n1/2(β10 − β̂1n)T (A11 −A12A−122A21)n1/2(β10 − β̂1n) + op(1).
The last equation comes from β̂20−β20 = β̂2n−β20+A−122A21(β̂1n−β10)+op(1). Thus
Corollary 3.7 holds because n1/2(β̂1n−β10) converges in distribution to N(0, (A11
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A12A
−1
22A21)
−1) under H˜0. 
Proof of Theorem 3.8. Following the same steps as in the proof of Theorem 3.3,
we can show that
n1/2A−1/2(β̂n − β0)→ N(A−1/2h, I).
Taking the Taylor series expansion of the empirical likelihood ratio test statistic at
β0, we have
T1n = n
1/2(β̂n − βa + h/
√
n)TA(β0)n
1/2(β̂n − βa + h/
√
n) + op(1),
where the second equality comes from βa = β0 + h/
√
n being a sequence of con-
tiguous alternatives. Therefore, T1n → χ2q with noncentrality parameter hTAh as
n→∞ under the alternative Ha : β = βa = β0 + h/
√
n. 
Proof of Corollary 3.9. Similar to the preceding proof, we have under the contiguous
alternative
T2n = n
1/2(β10 − β̂1n)T (A11 −A12A−122A21)n1/2(β10 − β̂1n) + op(1).
Similar to Theorem 3.3, we can show that when H˜a : β1 = β1a = β10 + h1/
√
n is
true, (A11 −A12A−122A21)−1/2n1/2(β10 − β̂1n) converges in distribution to N((A11 −
A12A
−1
22A21)
−1/2h1, I), which implies Corollary 3.9. 
In the following part of the APPENDIX, we verify that g∗rn in the examples follow-
ing Corollary 3.4 satisfies Condition C1. The other conditions are satisfied trivially.
Since the Fourier basis are naturally bounded by 1, the uniform boundedness reduces
to the boundedness ofm which is of finite dimension and usually holds easily. So (i)
is satisfied. Let
V n = ((11 − pi1)/pi1, s11, c11, . . . , s1dn , c1dn , (12 − pi2)/pi2, s21, c21, . . . , s2dn , c2dn)T
28
and grn(β) = (m
T (β; Y, Z),V Tn )
T , where 1k = 1(Z=k), sij =
√
2(1i−pii) sin(2pijF (X))/pii,
cij =
√
2(1i − pii) cos(2pijF (X))/pii, i = 1, 2, j = 1, . . . , dn. For notation simplicity,
we omitW n inW nV n when there is no ambiguity. Then letting Id denote the d×d
identity matrix, we have the following matrix partition
Σn,g =


E(mmT ) E(mV Tn )
1−π1
π1
I2dn+1 −I2dn+1
E(V nm
T ) −I2dn+1 1−π2π2 I2dn+1

 .
Thus, by some simple algebra and C3, we can show that the eigenvalues of Σn,g are
bounded away from 0 and ∞. However, since F is unknown in practice, we typically
use Fn(x) = n
−1
∑n
i=1 1{Xi≤x} instead. Let
V̂
T
n (z, x) = ((11 − pi1)/pi1, ŝ11, ĉ11, . . . , ŝ1dn , ĉ1dn , (12 − pi2)/pi2, ŝ21, ĉ21, . . . , ŝ2dn , ĉ2dn)
and ĝrn(β) = (m
T (β; Y, Z), V̂
T
n (Z,X))
T , where ŝij =
√
2(1i − pii) sin(2pijFn(x))/pii,
ĉij =
√
2(1i − pii) cos(2pijFn(x))/pii, i = 1, 2, j = 1, . . . , dn. Define εn = ĝrnĝTrn −
grng
T
rn. Then
rnmax
j,k
|εn,j,k| ≤ 2M2rn |sin pidn(Fn(X)− F (X))|
= Op(r
2
nn
−1/2).
Following the argument in Lemma 2, when we let rn = o(n
1
4 ), we know the eigenvalues
of E(ĝrn(β0)ĝ
T
rn(β0)) are also bounded away from zero and infinity. So (ii) holds.
Moreover, let f(z, x) =
∑K
k=0(1k − pik)E(m(β; Y, Z)|Z = k, x) and An be the
Fourier coefficients in the Fourier expansion of f(z, x) with the Fourier basis specified
in V̂ n(z, x). We know from Fourier approximation theory that AnV̂ n(z, x)→ f(z, x)
uniformly. Thus, by Condition C3 and the Dominated Convergence Theorem, (iii) is
satisfied. 
Proof of the validity of the plug-in estimator Fn. Checking the derivation of all the
theorems, we find that the following two conditions will guarantee the validity of the
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theorems when F is replaced by Fn∥∥∥∥∥n−1/2
n∑
i=1
(gˆn,i − gn,i)
∥∥∥∥∥ = op(1)(30) ∥∥∥∥∥n−1
n∑
i=1
{
gˆn,igˆ
T
n,i − gn,igTn,i
}∥∥∥∥∥ = op(1),(31)
where gn,i and gˆn,i are grn and gˆrn evaluated at the i
th sample. The norm of a matrix
M is defined to be sup
u
‖Mu‖, where u is a unit vector. The sufficiency of the above
two conditions when the number of constraints is fixed can be seen from the existing
literature (see, for example, Hjort et al. (2009)).
Denote the jth component of a vector g by gj. Then, for any j, we have
E
[{
n−1/2
n∑
i=1
(gˆjn,i − gjn,i)
}2∣∣∣∣X1, . . . ,Xn
]
≤ C1r2n ‖Fn − F‖2∞ ,
where C1 is a universal constant. Therefore,
E
{∥∥∥∥∥n−1/2
n∑
i=1
(gˆn,i − gn,i)
∥∥∥∥∥
2 ∣∣∣∣X1, . . . ,Xn
}
≤ C1r3n ‖Fn − F‖2∞ = Op(r3n/n),
which converges to 0 in probability due to C2. By Chebyshev’s inequality, we know
that for any ε > 0,
P
{∥∥∥∥∥n−1/2
n∑
i=1
(gˆn,i − gn,i)
∥∥∥∥∥ ≥ ε
∣∣∣∣X1, . . . ,Xn
}
= op(1),
which implies (30) due to the dominated convergence theorem.
Denote εu = n
−1
∑n
i=1
{
gˆn,igˆ
T
n,i−gn,igTn,i
}
u. Then we have E{(εju)2|X1, . . . ,Xn} ≤
Op(r
3
nn
−2) uniformly for u and j. Therefore, E{‖εu‖2 |X1, . . . ,Xn} ≤ Op(r4nn−2) ≤
op(1), which implies (31). 
References
[1] Armitage, P. (1981), “Importance of Prognostic Factors in the Analysis of Data from Clinical
Trials”, Controlled Clinical Trials, 1, 347-353.
[2] Billingsley, P. (1986), Probability and Measure, New York: Wiley.
[3] Cox, D. R. and Hinkley, D. V. (1974), Theoretical statistics, London: Chapman and Hall/CRC.
30
[4] Davidian, M., Tsiatis, A. A. and Leon, S. (2005), “Semiparametric Estimation of Treatment
Effect in a Pretest-Posttest Study with Missing Data (with discussion),” Statistical Science, 20,
261-301.
[5] Friedman, L. M., Furberg, C. D. and DeMets, D. L. (1998), Fundamentals of Clinical Trials,
New York: Springer-Verlag.
[6] Gail, M. H., Wieand, S. and Piantadosi, S. (1984), “Biased Estimates of Treatment Effect in
Randomized Experiments with Nonlinear Regressions and Omitted Covariates,” Biometrika,
71, 431-444.
[7] Goldambe, V. P. and Heyde, C. C. (1987), “Quasi-Likelihood and Optimal Estimation,” Inter-
national Statistical Review, 55, 231-244.
[8] Hajek, J., Sidak, Z. and Sen P. (1999),Theory of Rank Tests, San Diego, Calif. : Academic
Press.
[9] Hjort, N. L., McKeague, I. W. and Keilegom, I. V. (2009), “Extending the Scope of Empirical
Likelihood,” The Annals of Statistics, 37, 1079-1111.
[10] Huber, P. J. (1981), Robust Statistics, New York: Wiley.
[11] Kiefer, J. and Wolfowitz, J. (1956), “Consistency of the Maximum Likelihood Estimator in
the Presence of Infinitely Many Incidental Parameters,” Annals of Mathematical Statistics, 27,
887-906.
[12] Koch, G. G., Tangen, C. M., Jung, J. W. and Amara, I. A. (1998), “Issues for Covariate
Analysis of Dichotomous and Ordered Categorical Data from Randomized Clinical Trials and
Non-Parametric Strategies for Addressing Them,” Statistics in Medicine, 17, 1863-1892.
[13] Lang, S. (1987), Calculus of several variables, New York : Springer-Verlag.
[14] Leon, S., Tsiatis, A. A. and Davidian, M. (2003), “Semiparametric Estimation of Treatment
Effect in a Pretest-Posttest Study with Missing Data,” Biometrics, 59, 1048-1057.
[15] Lu, X. and Tsiatis, A. A. (2008), “Improving the efficiency of the log-rank test using auxiliary
covariates,” Biometrika, 95, 679-694.
[16] McCullagh, P. and Nelder, J. A. (1989), Generalized Linear Models, London: Chapman and
Hall.
[17] Owen, A. B. (1988), “Empirical Likelihood Ratio Confidence Intervals for a Single Functional,”
Biometrika, 75, 237-249.
[18] Owen, A. B. (1990), “Empirical Likelihood Ratio Confidence Regions,” The Annals of Statistics,
18, 90-120.
31
[19] Owen, A. B. (1991), “Empirical Likelihood for Linear Models,” The Annals of Statistics, 19,
1725-1747.
[20] Owen, A. B. (2001), Empirical Likelihood, Boca Raton: Chapman and Hall/CRC.
[21] Piantadosi, S. (2005), Clinical Trials: A Methodologic Perspective, New Jersey: Wiley.
[22] Pocock, S. J. (1983), Clinical Trials: A practical Approach, New York: Wiley.
[23] Pocock, S. J., Assmann, S. E., Enos, L. E. and Kasten, L. E. (2002), “Subgroup Analysis,
Covariate Adjustment and Baseline Comparisons in Clinical Trial Reporting: Current Practice
and Problems,” Statistics in Medicine, 21, 2917-2930.
[24] Portnoy, S. (1988), “Asymptotic Behavior of Likelihood Methods for Exponential Families when
the Number of Parameters Tends to Infinity,” The Annals of Statistics, 16, 356-366.
[25] Qin, J. and Lawless, J. (1994), “Empirical Likelihood and General Estimating Equations,” The
Annals of Statistics, 22, 300-325.
[26] Robinson, L. D. and Jewell, N. P. (1991), “Some Surprising Results about Covariate Adjustment
in Logistic Regression Models,” International Statistical Review, 58, 227-240.
[27] Rutter, C. M. and Elashoff, R. M. (1994), “Analysis of Longitudinal Data: Random Coefficient
Regression Modeling,” Statistics in Medicine, 13, 1211-1231.
[28] Scheffe, H. (1959), The Analysis of Variance, New York : John Wiley and Sons, Inc.
[29] Serfling, R.J. (2002), Approximation Theorems of Mathematical Statistics, New York : Wiley.
[30] Simon, R. (1984), Use of Regression Models: Statistical Aspects. In M.J. Staquet, and R.J.
Sylvester (eds.), Cancer Clinical Trials., Oxford: Oxford University Press.
[31] Steyerberg, E. W., Bossuyt, P. M. M. and Lee, K. L. (2000), “Clinical Trials in Acute Myocardial
Infarction: Should we Adjust for Baseline Characteristics?,” American Heart Journal, 139, 745-
751.
[32] Tsiatis, A. A., Davidian, M., Zhang, M. and Lu, X. (2008), “Covariate Adjustment for Two-
Sample Treatment Comparisons in Randomized Clinical Trials: A Principle yet Flexible Ap-
proach,” Statistics in Medicine, 27, 4658-4677.
[33] Zedlewski, J.(2008), Practical Empirical Likelihood Estimation with matElike.
[34] Zhang, M., Tsiatis, A. A., and Davidian, M. (2008), “Improving Efficiency of Inferences in
Randomized Clinical Trials Using Auxiliary Covariates,” Biometrics, 64, 707-715.
32
Table 1. Bias and Standard Error Comparisons When Logit is Linear
in X.
Method True β MC Bias OptStd MC Std CovProb avlen
X ∼ N(0, 0.52)
marginal 0.2832 0.0033 0.1992 0.2025 0.9520 0.7960
0.6096 0.0063 0.2872 0.3007 0.9486 1.1801
5 Fourier 0.2832 0.0036 0.1992 0.2027 0.9500 0.7870
0.6096 0.0056 0.2872 0.2968 0.9468 1.1536
X ∼ N(0, 12)
marginal 0.2479 0.0010 0.1929 0.2025 0.9520 0.7940
0.4634 0.0063 0.2585 0.2988 0.9472 1.1562
5 Fourier 0.2479 0.0011 0.1929 0.1992 0.9496 0.7718
0.4634 0.0049 0.2585 0.2812 0.9424 1.0785
X ∼ N(0, 22)
marginal 0.1814 0.0040 0.1800 0.1995 0.9526 0.7912
0.2792 0.0003 0.2110 0.2951 0.9452 1.1324
5 Fourier 0.1814 0.0043 0.1800 0.1873 0.9518 0.7337
0.2792 -0.0018 0.2110 0.2439 0.9418 0.9292
7 Fourier 0.1814 0.0030 0.1800 0.1860 0.9494 0.7186
0.2792 0.0008 0.2110 0.2341 0.9442 0.8846
9 Fourier 0.1814 0.0032 0.1800 0.1857 0.9464 0.7101
0.2792 0.0008 0.2110 0.2311 0.9384 0.8631
11 Fourier 0.1814 0.0032 0.1800 0.1852 0.9448 0.7037
0.2792 0.0007 0.2110 0.2293 0.9340 0.8490
NOTE: In all the tables, ‘marginal’ means using empirical likelihood method with 2
marginal estimating equations Y − φ(β1 + β2Z) and Z
(
Y − φ(β1 + β2Z)
)
, while “5
Fourier” has three additional estimating equations 2Z − 1, √2(2Z − 1) sin[2piFn(X)]
and
√
2(2Z − 1) cos[2piFn(X)], where Fn(X) is the empirical cumulative distribution
function of X. MC Bias is Monte Carlo bias, OptStd is the asymptotic standard error
obtained according to the sandwich formula, MC Std is the Monte Carlo standard
error, CovProb is the coverage probability of 95% Wald confidence intervals and avlen
is the average length of those confidence intervals.
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Table 2. Bias and Standard Error Comparisons When Logit is Qua-
dratic in X.
Method True β MC Bias OptStd MC Std CovProb avlen
X ∼ N(0, 0.52)
marginal 0.5298 0.0057 0.2059 0.2093 0.9516 0.8160
0.7758 0.0094 0.3169 0.3266 0.9536 1.2683
5 Fourier 0.5298 0.0061 0.2059 0.2088 0.9480 0.8090
0.7758 0.0088 0.3169 0.3257 0.9524 1.2523
X ∼ N(0, 12)
marginal 0.9664 0.0106 0.2182 0.2307 0.9476 0.8845
0.8105 0.0182 0.3466 0.3795 0.9494 1.4450
5 Fourier 0.9664 0.0111 0.2182 0.2254 0.9448 0.8604
0.8105 0.0156 0.3466 0.3648 0.9502 1.3800
Table 3. Bias and Standard Error Comparisons When Logit Contains
Two Covariates.
Method True β MC Bias OptStd MC Std CovProb avlen
X1 ∼ N(0, 12), X2 ∼ N(0, 22)
marginal 0.1061 -0.0003 0.1649 0.2005 0.9558 0.7883
0.3157 0.0043 0.1828 0.2933 0.9494 1.1282
7 Fourier 0.1061 -0.0009 0.1649 0.1761 0.9526 0.6813
0.3157 0.0051 0.1828 0.2311 0.9438 0.8716
X1 ∼ N2(0, 12), X2 ∼ N(0, 22)
marginal 0.4389 0.0063 0.1688 0.2032 0.9550 0.8069
0.5493 0.0056 0.1985 0.3072 0.9486 1.2023
7 Fourier 0.4389 0.0052 0.1688 0.1825 0.9494 0.7012
0.5493 0.0041 0.1985 0.2490 0.9458 0.9396
X1 ∼ N2(0, 0.52), X2 ∼ N2(0, 12)
marginal 1.4746 0.0149 0.2482 0.2594 0.9562 1.0201
0.5813 0.0233 0.3857 0.4310 0.9498 1.6363
7 Fourier 1.4746 0.0144 0.2482 0.2512 0.9518 0.9771
0.5813 0.0224 0.3857 0.4126 0.9486 1.5485
NOTE: The logit is either quadratic (X ∼ N2(·, ·)) or linear (X ∼ N(·, ·)) in each
covariate.
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Table 4. Power Comparison When Logit is Linear in X.
marginal 5 Fourier
X β10 β20 CovProb Power CovProb Power
N(0, 0.52) 0.2125 0.8304 0.9498 0.7928 0.9492 0.8216
N(0, 12) 0.1379 0.8207 0.9494 0.7826 0.9458 0.8682
N(0, 22) 0.0386 0.8182 0.9486 0.7938 0.9436 0.9568
Table 5. Power Comparison When Logit is Quadratic in X.
marginal 5 Fourier
X β10 β20 CovProb Power CovProb Power
N(0, 0.52) 0.8511 1.0599 0.9442 0.8428 0.9448 0.8498
N(0, 12) 0.9662 0.9359 0.9464 0.7356 0.9482 0.7724
Table 6. Power Comparison When Logit Contains Two Covariates.
marginal 7 Fourier
X1, X2 β10 β20 CovProb Power CovProb Power
N(0, 12), N(0, 22) 0.0694 0.8461 0.9488 0.8166 0.9430 0.9308
N2(0, 12), N(0, 22) 0.2468 0.7012 0.9418 0.6584 0.9438 0.8636
N2(0, 0.52), N2(0, 12) 1.1701 0.8342 0.9496 0.5873 0.9478 0.6140
NOTE: In each scenario, β10 and β20 are the true values. The profile empirical
likelihood ratio test is used to test the null hypothesis H˜0 : β2 = 0. CovProb are the
coverage probabilities of tests β2 = β20.
